Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 25, Issue 2 (March 2023) 25, 192–197; 10.4103/aja2022105

The role of glutamine metabolism in castration-resistant prostate cancer

Zhao, Bing1; Wang, Jing2; Chen, Li1; Wang, Hong3; Liang, Chao-Zhao4,5,6; Huang, Jiaoti7,8,; Xu, Ling-Fan4,5,6

1Department of Geriatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230002, China

2Department of Urologic Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China

3Department of Nursing, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China

4Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China

5Institute of Urology, Anhui Medical University, Hefei 230001, China

6Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230001, China

7Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA

8Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA

Correspondence: Dr. J Huang (Jiaoti.huang@duke.edu) Dr. LF Xu (ayfyxlf@163.com)

Received: 20 August 2022; Accepted: 17 November 2022; published online: 10 January 2023

Abstract

Reprogramming of metabolism is a hallmark of tumors, which has been explored for therapeutic purposes. Prostate cancer (PCa), particularly advanced and therapy-resistant PCa, displays unique metabolic properties. Targeting metabolic vulnerabilities in PCa may benefit patients who have exhausted currently available treatment options and improve clinical outcomes. Among the many nutrients, glutamine has been shown to play a central role in the metabolic reprogramming of advanced PCa. In addition to amino acid metabolism, glutamine is also widely involved in the synthesis of other macromolecules and biomasses. Targeting glutamine metabolic network by maximally inhibiting glutamine utilization in tumor cells may significantly add to treatment options for many patients. This review summarizes the metabolic landscape of PCa, with a particular focus on recent studies of how glutamine metabolism alterations affect therapeutic resistance and disease progression of PCa, and suggests novel therapeutic strategies.

Keywords: castration resistance; glutamine metabolism; prostate cancer; tumor metabolism

Full Text | PDF |

 
Browse:  284
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.